Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized azithromycin + metronidazole adjunctive therapy in pediatric Crohn's disease
2019-004219-29Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azithromycin and metronidazole in Crohn's disease, sponsored by Amsterdam University Medical Center. Primary endpoint: Sustained remission at 12 months. Started Feb 2020; status: completed.
02
Drugs
azithromycinmetronidazole
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2019-004219-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004219-29.